SUMMARY  

• SPRAVATO nasal spray is intended for administration by the patient under the supervision of a healthcare professional, using 2 devices (for a 56 mg dose) or 3 devices (for an 84 mg dose), with a 5-minute rest between use of each device to allow medication to be absorbed.¹
• To prevent loss of medication, do not prime the device before use.¹
• SPRAVATO is an aqueous solution of esketamine HCl and is not a pulmonary aerosol. Pulmonary aerosols are characterized in part by their percentage of fine particles (<5 µm) needed for delivery of medication to the lungs.^2,3 In contrast, SPRAVATO, with its larger particle size is intended to deliver medication into the nasal cavity.⁴
• Because of the product characteristics of SPRAVATO, the potential for aerosol generation following nasal administration of SPRAVATO has not been studied, however:
  • SPRAVATO was designed to minimize the percentage of small droplets (<10µm).⁵
  • If accidentally sprayed into the air, it is estimated that the contents may extend to approximately 500-600 mm (about 20-24 inches).⁵
• As per the INSTRUCTIONS FOR USE (IFU), patients are instructed to only spray into the nostril.¹ As such, the liquid droplets should stay inside the nasal cavities after the patient sprays the device.
  • The patient should be instructed to sniff gently after spraying to keep the medication inside the nose.
  • The correct positioning of the nasal spray device by the patient is aided with a nose rest. The nose rest is designed to position the spray tip for optimal spray delivery into the nasal cavity.

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 03 January 2025.